22.09.2020 23:55:00

Introducing Droplet Micron™, The Shortest and Thinnest Pen Needle, Ever

Designed to Deliver the Best Injection Experience

MARIETTA, Ga., Sept. 22, 2020 /CNW/ -- HTL-STREFA today announced the release of Droplet Micron, a new and innovative pen needle designed to deliver the best injection experience.

Droplet Micron 34G x 3.5mm Pen Needles, 100 count box

At 34G x 3.5mm, Droplet Micron is thinner and shorter than other pen needles available today. Droplet Micron reduces the penetration force required for an injection up to 50%, previous research has linked reduction in penetration force to a less painful injection experience.

Despite the reduction in needle size, Droplet Micron delivers the same reliability, safety, and effectiveness that traditional pen needles offer. In addition, another Droplet Micron innovation – its tapered and polished needle tip is designed for maximum comfort, prompting 98% of people to recommend it to others. 

These are important innovations; for those that rely on insulin injections, a better injection experience means more than just the moment of injection. Research suggests that 94% of insulin injectors experience related anxiety and distress, the result of daily triggers (from anticipating the injection, to seeing the needle, to the injection itself). These anxious feelings and experiences, can jeopardize medication adherence. Put more simply, medication delivery will always be important – but the injection experience can no longer be ignored.

The "injection experience" is more than a moment – it is a cyclical journey, where the feelings that surround anticipation, preparation, and injection have a cumulative impact. Droplet Micron was designed to help break this routinely anxious cycle so that people injecting diabetes medications, feel better about every injection, every time.

"Every aspect of Droplet Micron was designed with experience in mind," said Carl Ward, General Manager, Americas at HTL-STREFA, Inc. "In a product category where 'how it works' has always been the focus, 'what people are feeling' hasn't always been top-of-mind. At HTL-STREFA, we don't think that people with diabetes should have to compromise on any aspect of their injection experience. When you use Droplet Micron for the first time, you can see and feel the difference immediately, and feel better about every injection that comes after."

"Droplet Micron is the result of our continuous focus on innovation in diabetes care," concludes Carl Ward. "Every day, people with diabetes do their part in managing their health by taking their injectable diabetes medication. Micron's here, it's in their corner, every day at every injection."

Droplet Micron is now available at your local pharmacy. For more information about Droplet Micron, talk with your healthcare provider, ask your pharmacist, or visit www.mydroplet.com

HTL-STREFA®: HTL-STREFA is a company of MTD Medical Technology and Devices, a swiss leading med-tech group, playing an important role within the social and health care network worldwide, through its daily commitment to improve health care and make it accessible, safe, and easy. HTL-STREFA is a world-leading medical device company that develops, manufactures, and sells safety lancets, personal lancets, lancing devices, pen needles, and safety pen needles. Our modern manufacturing process and nearly 20 years of experience on the global market allows us to successfully ensure safety and convenience. We employ a continuous improvement strategy to analyze and update products, implementing improvements and launching new solutions to meet the changing needs of both patients and health care professionals. HTL-STREFA, Inc. is the distributor for HTL-STREFA S.A. www.htl-strefa.com  www.mydroplet.com

Media Contact:
Jessica Forrest
678-265-4319
jessica.forrest@htl-strefa.com  

SOURCE HTL-STREFA, Inc.

Eintrag hinzufügen
Hinweis: Sie möchten dieses Wertpapier günstig handeln? Sparen Sie sich unnötige Gebühren! Bei finanzen.net Brokerage handeln Sie Ihre Wertpapiere für nur 5 Euro Orderprovision* pro Trade? Hier informieren!
Es ist ein Fehler aufgetreten!